CME

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

Overview

Author(s)/Faculty: Michael Miller, MD, FACC, FAHA; Christopher P. Cannon, MD; Peter Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FASPC, FCCP, FACC; Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA, FESC
Source: Healio - Cardiology Education Lab
Type: MonographArticles/Items: 5
Release Date: 6/30/2017Expiration Date: 6/30/2018
Credit Type: CMENumber of Credits: 1.25
Cost: FreeProvider: Vindico Medical Education

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic cardiovascular disease. Despite highly effective statin therapy, some patients fail to achieve desired LDL-C reductions, and therefore remain at high risk of a cardiovascular event. For these patients, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising new strategy. In this activity, expert faculty will review the latest evidence from recent clinical trials of PCSK9 inhibitors, the guidelines for cardiovascular risk assessment, and the safety of LDL-C lowering.

CME Information

page 1 of 8